Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05494606
Other study ID # P22-921
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date August 15, 2022
Est. completion date March 31, 2028

Study information

Verified date May 2024
Source AbbVie
Contact ABBVIE CALL CENTER
Phone 844-663-3742
Email abbvieclinicaltrials@abbvie.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Ulcerative colitis (UC) is an idiopathic, chronic, inflammatory disease affecting the colon. Participants with UC have mucosal inflammation starting in the rectum that can extend continuously to proximal segments of the colon. This study will assess how safe and effective upadacitinib is in treating adult participants with moderate to severe ulcerative colitis (UC). Adverse events and change in disease activity will be assessed. Upadacitinib is a drug approved for the treatment of Ulcerative colitis (UC). All study participants will receive upadacitinib as prescribed by their study doctor in accordance with approved local label. Approximately 1000 adult participants will be enrolled worldwide. Participants will receive upadacitinib as prescribed by their physician according to their routine clinical practice and local label. Participants will be followed for up to 3 years. There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.


Recruitment information / eligibility

Status Recruiting
Enrollment 1000
Est. completion date March 31, 2028
Est. primary completion date March 31, 2028
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Participants with a diagnosis of moderate to severe Ulcerative colitis (UC). - Participants initiating upadacitinib at the clinician's discretion as part of their routine clinical care; the decision to administer upadacitinib must be made prior to and independent of recruitment into the study. - Participants prescribed upadacitinib in accordance with the approved local label. - Participants able to understand and communicate with the investigator and comply with the requirements of the study. - Participants willing to continue with study documentation after cessation of upadacitinib. - Participants willing and able to participate in the collection of patient-reported data via cloud based mobile application using the provided smart device (iPhone). Exclusion Criteria: - Participants with any contraindication to upadacitinib. - Participants previously exposed to upadacitinib in a clinical trial. - Participants currently participating in interventional research (not including noninterventional study, postmarketing observational study (PMOS), or registry participation).

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Argentina Gedyt /ID# 249611 Ciudad Autonoma de Buenos Aire Ciudad Autonoma De Buenos Aires
Argentina Hospital Britanico de Buenos Aires /ID# 249605 Ciudad Autonoma de Buenos Aire Ciudad Autonoma De Buenos Aires
Argentina Hospital Privado Universitario - Hospital Privado Centro Medico de Cordoba S.A. /ID# 249612 Cordoba
Australia Blacktown Hospital /ID# 248354 Blacktown New South Wales
Australia Austin Health /ID# 249133 Heidelberg Victoria
Australia Nepean Hospital /ID# 248351 Kingswood New South Wales
Australia Coral Sea Clinical Research institute /ID# 248352 North Mackay Queensland
Australia The Royal Melbourne Hospital /ID# 248353 Parkville Victoria
Canada Barrie GI Associates /ID# 264978 Barrie Ontario
Canada University of Calgary /ID# 259183 Calgary Alberta
Canada Dr. J Siffledeen Profess Pract /ID# 256903 Edmonton Alberta
Canada Gastroenterology and Internal Medicine Research Institution /ID# 251463 Edmonton Alberta
Canada Hamilton Health Sciences - McMaster University Medical Centre /ID# 256819 Hamilton Ontario
Canada Dr. Sundeep Singh, Inc /ID# 251471 Kelowna British Columbia
Canada Six08 Gastroenterology /ID# 259452 Lethbridge Alberta
Canada London Health Sciences Center- University Hospital /ID# 258472 London Ontario
Canada West GTA Endoscopy /ID# 263221 Mississauga Ontario
Canada The Moncton Hospital /ID# 257337 Moncton New Brunswick
Canada Scott Shulman Medicine Professional Corporation /ID# 256826 North Bay Ontario
Canada Toronto Immune and Digestive Health Institute Inc /ID# 256827 North York Ontario
Canada Diex Recherche Québec Inc. /ID# 262796 Québec Quebec
Canada Toronto Digestive Disease Associates, Inc. /ID# 258914 Vaughan Ontario
Czechia Nemocnice Ceske Budejovice a.s. /ID# 259810 Ceske Budejovice
Czechia ISCARE a.s. /ID# 259811 Prague Praha 9
Czechia Fakultni nemocnice Kralovske Vinohrady /ID# 261535 Praha
France Clinique de l'Europe /ID# 251851 Amiens Somme
France CHU Amiens-Picardie Site Sud /ID# 252103 Amiens CEDEX 1 Somme
France Centre Hospitalier D'Avignon /ID# 252657 Avignon
France Centre Hospitalier de la Cote Basque /ID# 252358 Bayonne Pyrenees-Atlantiques
France CHU de Besancon - Jean Minjoz /ID# 252966 Besancon Doubs
France Ch Bethune - Beuvry /Id# 252233 Bethune CEDEX
France Pole Sante Saint-Jean /ID# 252235 Cagnes Sur Mer
France Hopitaux Civils de Colmar /ID# 252496 Colmar
France CH Annecy Genevois - Site Annecy /ID# 253010 Epagny Metz Tessy
France CHU Grenoble-Alpes /ID# 251937 La tronche
France CHRU Lille - Hopital Claude Huriez /ID# 251971 Lille Nord
France APHM - Hopital Nord /ID# 252049 Marseille Bouches-du-Rhone
France GHI Le Raincy - Montfermeil /ID# 252733 Montfermeil
France CHU Montpellier - Hôpital Saint Eloi /ID# 252041 Montpellier Cedex 5 Herault
France Clinique Jules Verne /ID# 251969 Nantes
France Centre Medico Chirurgical Ambroise Pare Hartmann /ID# 252565 Neuilly Sur Seine Ile-de-France
France Chu de Nice-Hopital Larchet Ii /Id# 251938 Nice Alpes-Maritimes
France CHU NIMES - Hopital Caremeau /ID# 254790 Nimes CEDEX 9 Gard
France Centre Hospitalier Régional d'Orléans - Hôpital de la Source /ID# 252125 Orléans
France Institut Mutualiste Montsouris /ID# 251849 Paris
France HCL - Hopital Lyon Sud /ID# 252093 Pierre Benite CEDEX Rhone
France CHU Reims - Hôpital Robert Debre /ID# 252017 Reims CEDEX Marne
France CHRU Pontchaillou /ID# 252015 Rennes
France Clinique Santé Atlantique /ID# 252581 St Herblain CEDEX Loire-Atlantique
France Centre Hospitalier Universitaire de Saint Étienne - Hôpital Nord /ID# 252265 St-Priest-en-Jarez
France Centres des maladies de l'appareil digestif /ID# 252283 Strasbourg
France CHU Toulouse - Hopital Rangueil /ID# 251879 Toulouse Haute-Garonne
France Clinique Pasteur /ID# 251893 Toulouse CEDEX 3
France Hôpital Schuman /ID# 252995 Vantoux
Germany Dr. Bernd Adami /ID# 248123 Alzey
Germany Dr. Heil /ID# 248273 Andernach
Germany Charité Universitätsmedizin Berlin - Campus Mitte /ID# 248979 Berlin
Germany Praxis Dr. Michael Mross /ID# 248272 Berlin
Germany Krankenhaus Waldfriede /ID# 248307 Berlin-Zehlendorf
Germany Praxis S. Tetzlaff /ID# 248263 Büdelsdorf Schleswig-Holstein
Germany Medizinisches Versorgunszentrum Dachau /ID# 257231 Dachau
Germany Praxis Dres. Hurst/Simonis /ID# 255159 Darmstadt
Germany Praxis Dr. Lukas Buendgens & Dr. Burkhard Buendgens /ID# 254873 Eschweiler
Germany Interdisziplinaeres Crohn Colitis Zentrum /ID# 252224 Frankfurt
Germany Markus Krankenhaus /ID# 260648 Frankfurt am Main Hessen
Germany Dres. Bauer/Doerflinger /ID# 252107 Freiburg im Breisgau
Germany Dr. Zeisler, Halle, DE /ID# 250126 Halle
Germany Dres. Behrens/Fechner/Streudel /ID# 250872 Halle (Saale)
Germany Miamedes Hausarztpraxis Altona /ID# 260064 Hamburg
Germany Medizinische Hochschule Hannover /ID# 257454 Hannover
Germany GSGH Gastroenterologische Studiengesellschaft Herne GbR /ID# 250262 Herne
Germany Gastroenterologie Opernstrasse Private Practice - Dr. Falk & Krause & Kuhn /ID# 252076 Kassel
Germany Thurman/Bethge /ID# 248305 Kiel
Germany Dres. Breitschwerdt/Glas/Gurtler /ID# 251192 Leipzig
Germany Internistische Gemienschaftspraxis fuer Verdauungs- und Stoffwechselerkrankungen /ID# 250873 Leipzig
Germany Dres. Schmidt/Büning/Bär, Praxis für Gastroenterologie /ID# 250749 Lübeck Schleswig-Holstein
Germany Universitaetsklinikum Schleswig-Holstein Campus Luebeck /ID# 251273 Lübeck Schleswig-Holstein
Germany Duplicate_St. Marien- und Annastiftskrankenhaus /ID# 255158 Ludwigshafen am Rhein Rheinland-Pfalz
Germany Gastro Campus Research GbR /ID# 249867 Muenster
Germany Bettenworth & Partner /ID# 248977 Münster
Germany Gastro.Praxis am Meerbachbogen /ID# 251856 Nienburg (Weser)
Germany Praxis Dres Brendel /ID# 250559 Nuernberg
Germany Magen-Darm-Zentrum-Remscheid /ID# 250339 Remscheid Nordrhein-Westfalen
Germany Schwerpunktpraxis Gastroenterologie Dr. Ingomar Scheller /ID# 250581 Remscheid
Germany Zentrum für Gastroenterologie Saar MVZ GmbH /ID# 251824 Saarbrücken Saarland
Germany Praxis Dr. Kempelmann /ID# 257748 Tostedt
Greece Alexandra General Hospital /ID# 260786 Athens Attiki
Greece General Hospital of Athens Evaggelismos and Ophthalmiatrio of Athens Polyclinic /ID# 259870 Athens
Greece General Hospital of Chest Diseases of Athens SOTIRIA /ID# 260787 Athens Attiki
Greece University General Hospital of Heraklion PA.G.N.I /ID# 259869 Heraklion Kriti
Greece General Hospital of Nikaia-Piraeus "Agios Panteleimon" /ID# 250794 Nikaia
Greece General Hospital of Thessaloniki Hippokrateio /ID# 260785 Thessaloniki
Ireland Connolly Hospital Blanchardstown /ID# 252190 Abbotstown Dublin
Ireland St Vincent's University Hospital /ID# 251855 Elm Park Dublin
Ireland University Hospital Galway /ID# 253427 Galway
Israel Soroka University Medical Center /ID# 249885 Be'er Sheva HaDarom
Israel Shamir Medical Center /ID# 256885 Beer Ya'akov HaMerkaz
Israel Rabin Medical Center /ID# 249474 Haifa
Israel Rambam Health Care Campus /ID# 249884 Haifa H_efa
Israel Tel Aviv Sourasky Medical Center /ID# 250562 Tel Aviv Tel-Aviv
Italy Ospedale San Raffaele IRCCS /ID# 261058 Milan Milano
Italy Azienda Ospedaliera Universitaria Federico II /ID# 260802 Napoli
Italy A.O. Ospedali Riuniti Villa Sofia - Cervello /ID# 261052 Palermo
Italy Fondazione PTV Policlinico Tor Vergata /ID# 260811 Rome Roma
Italy Istituto Clinico Humanitas /ID# 260801 Rozzano Milano
Kuwait Mubarak Hospital /ID# 252026 Hawalli
Portugal Hospital Garcia de Orta /ID# 264420 Almada
Portugal Centro Hospitalar Universitário do Algarve, EPE - Hospital Faro /ID# 260517 Faro
Portugal Centro Hospitalar de Lisboa Ocidental, EPE - Hospital Egas Moniz /ID# 260524 Lisboa
Portugal Centro Hospitalar Universitario de Lisboa Norte, EPE - Hospital de Santa Maria /ID# 258759 Lisboa
Portugal Centro Hospitalar Universitario de Sao Joao, EPE /ID# 260038 Porto
Portugal Centro Hosp de Tondela-Viseu /ID# 258760 Viseu
Russian Federation Voronezh Regional Clinical Hospital #1 /ID# 249932 Voronezh
United Arab Emirates Burjeel Day Surgery Center /ID# 252030 Abu Dhabi
United Arab Emirates Cleveland Clinic Abu Dhabi /ID# 252038 Abu Dhabi
United Kingdom Hampshire Hospitals NHS Foundation Trust /ID# 261416 Basingstoke Essex
United Kingdom Ulster Hospital /ID# 255265 Belfast
United Kingdom Northern Care Alliance NHS Foundation Trust /ID# 253993 Bury Lancashire
United Kingdom Royal Devon & Exeter Hospital /ID# 252734 Exeter Devon
United Kingdom Hull University Teaching Hospitals NHS Trust /ID# 253988 Hull East Riding Of Yorkshire
United Kingdom Kettering General Hospital NHS Foundation Trust /ID# 255263 Kettering Northamptonshire
United Kingdom Liverpool University Hospitals NHS Foundation Trust /ID# 253989 Liverpool
United Kingdom Barts Health NHS Trust /ID# 252735 London
United Kingdom Nottingham City Hospital /ID# 255270 Nottingham Nottinghamshire
United Kingdom Oxford University Hospitals - John Radcliffe Hospital /ID# 265343 Oxford
United Kingdom St George's University Hospitals NHS Foundation Trust /ID# 255271 Tooting
United Kingdom New Cross Hospital /ID# 266364 Wolverhampton

Sponsors (1)

Lead Sponsor Collaborator
AbbVie

Countries where clinical trial is conducted

Argentina,  Australia,  Canada,  Czechia,  France,  Germany,  Greece,  Ireland,  Israel,  Italy,  Kuwait,  Portugal,  Russian Federation,  United Arab Emirates,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Median Time to Achieve the First Clinical Response (CR) per Partial Adapted Mayo Score The first clinical response (CR) per partial adapted mayo score is defined as a decrease from baseline in partial adapted mayo score = 1 point and = 30%, plus a decrease from baseline in the rectal bleeding score [RBS] = 1 or absolute RBS = 1. Median time to achieve the first CR per partial adapted mayo score will be reported Up to approximately week 156
Primary Percentage of Participants Achieving Clinical Response (CR) per Partial Adapted Mayo Score Among those who Achieved CR at Completion of Upadacitinib Induction (either at Week 8 or at Week 16) Clinical response (CR) per partial adapted mayo score is defined as a decrease from baseline in partial adapted mayo score = 1 point and = 30%, plus a decrease from baseline in the rectal bleeding score [RBS] = 1 or absolute RBS = 1. Week 52
See also
  Status Clinical Trial Phase
Recruiting NCT05702879 - Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success
Not yet recruiting NCT05953402 - A Study of Ozanimod in Pregnant Women With Ulcerative Colitis and Their Offspring
Recruiting NCT05316584 - A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy N/A
Recruiting NCT03950232 - An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis Phase 3
Completed NCT03124121 - Study of the Golimumab Exposure-Response Relationship Using Serum Trough Levels Phase 4
Not yet recruiting NCT06100289 - A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease Phase 3
Withdrawn NCT04209556 - A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis Phase 2
Terminated NCT00061282 - Clotrimazole Enemas for Pouchitis in Children and Adults Phase 1/Phase 2
Recruiting NCT04398550 - SCD vs. Mediterranean Diet Therapy in Ulcerative Colitis N/A
Recruiting NCT04314375 - Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis Phase 4
Active, not recruiting NCT04857112 - Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis Phase 2
Completed NCT05051943 - A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
Active, not recruiting NCT04033445 - A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis Phase 2/Phase 3
Recruiting NCT05428345 - A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea
Active, not recruiting NCT06221995 - Energy Expenditure in Patients With Ulcerative Colitis Undergoing Surgery
Recruiting NCT04767984 - Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis Phase 2
Completed NCT02508012 - Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases N/A
Recruiting NCT06071312 - FMT in Patients With Recurrent CDI and Ulcerative Colitis: Single Infusion Versus Sequential Approach Phase 1/Phase 2
Completed NCT03760003 - Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis Phase 2
Not yet recruiting NCT05539625 - Mini-MARVEL - Mitochondrial Antioxidant Therapy in Ulcerative Colitis Phase 2

External Links